Skip to main content
OpenTrials
Completed

NCT Number: NCT04299815

Lactate in the Gut

Lactate is formed naturally in the body in example during physical activity. However, lactate is also formed during food fermentation where certain bacterial strains form lactate. Lactate can also be produced chemically. An example of this is Ringer-lactate which is used for volume replacement when treating dehydrated patients.

As a source of carbon-molecules, lactate is believed to be an important oxidative fuel source in all major organs and yields adenosine triphosphate (ATP) production through Krebs cycle, the Electron Transport Chain in the mitochondria as well as by being a key precursor for gluconeogenesis.

Metformin is the first drug of choice for type 2 diabetes treatment. Use of metformin often results in a small but significant weight loss in overweight users. It is known that metformin increases the lactate concentration in the gut. It is also known also know that metformin use is associated with an increase in blood concentrations of growth differentiation factor 15 (GDF-15). Receptors for GDF-15 can be found in parts of the brain associated with control of appetite. In rats increases in [GDF-15] results in a decrease in appetite and thus weight loss. GDF-15 is thought to be involved in the normal energy homeostasis.

With this study the investigators want to examine the hormonal, metabolic and mechanical effects of lactate in the gut in healthy volunteers. Our hypothesis is that lactate has beneficial effects which may be though an increase in GDF-15 in the blood.

Volunteers will undergo two study days separated by at least 7 days and a maximum of 1 month.

* On day one volunteers will drink a sodium-lactate solution (intervention). The investigators will also administrate 1500mg paracetamol to assess gastric emptying and do blood samples over 4 hours. The investigators measure [lactate] every 15 min. Every hour the investigators will ask volunteers questions regarding hunger and thoughts of future food intake (questionnaire). After 4 hours of blood sampling the investigators will serve volunteers an all-you-can-eat meal of sandwich and measure how must they ate. * On day two volunteers will drink a sodium chloride solution. Furthermore, the investigators administrate intravenous D/L sodium lactate in order to reach the same plasma [lactate] on day 2 as was done on day 1. The rest of day two is identical to day 1.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–50 year

Sex eligibility

Male

Study type

Interventional

Phase

Not applicable

Primary location

Aarhus University Hospital

Aarhus, 8200, Denmark

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Male gender
  • Age 18-50 years
  • BMI 20-30 kg/m2
  • In good health with no daily use of prescription medicine based on medical history, clinical examination and blood samples.
  • Spoken and written informed consent

Exclusion criteria

  • Chronic illness or daily use of prescription medicine .
  • Abnormal screening blood samples as judged by the PI
  • Does not understand or speak Danish

Treatment and study plan

Oral Sodium Lactate

Drug

25 grams of D/L lactate dissolved in 300mL water.

Intravenous sodium lactate

Drug

intravenous sodium lactate + oral sodium-chlorid solution

Primary outcomes

  1. GDF-15

    Time frame: 4 hours

    Difference in [GDF-15] between intervention and placebo

Secondary outcomes

  1. glucagon-like peptide -1

    Time frame: 4 hours

    Difference in [glucagon-like peptide -1] between intervention and placebo

  2. Gastric inhibitory peptide (GIP)

    Time frame: 4 hours

    Difference in plasma [GIP] between intervention and placebo

  3. free fatty acid

    Time frame: 4 hours

    Difference in [free fatty acid ] between intervention and placebo

  4. cholecystokinin

    Time frame: 4 hours

    Difference in [cholecystokinin] between intervention and placebo

  5. Ghrelin

    Time frame: 4 hours

    Difference in [Ghrelin] between intervention and placebo

  6. Gastrin

    Time frame: 4 hours

    Difference in [Gastrin] between intervention and placebo

  7. C-peptide

    Time frame: 4 hours

    Difference in [C-peptide] between intervention and placebo

  8. glucose

    Time frame: 4 hours

    Difference in [glucose] between intervention and placebo

  9. gastric emptying

    Time frame: 4 hours

    [Paracetamol] to asses gastric emptying

  10. Evaluation of hunger

    Time frame: 4 hours

    Evaluation of hunger, thoughts of future food intake ect using a questionnaire

Sponsors and collaborators

Lead sponsor

University of Aarhus

Other

Registry information

Important dates

Study start
2020
Primary completion
2020
Study completion
2020
First posted
Mar 9, 2020
Registry last updated
Sep 30, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.